Manufacturer of Controlled Substances; Notice of Application, 45785-45786 [E8-18047]

Download as PDF 45785 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices Drug Schedule Methadone intermediate (9254) ... II The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17963 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 11, 2008, American Radiolabeled Chemical, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: mstockstill on PROD1PC66 with NOTICES Drug Schedule Gamma hydroxybutyric acid (2010). Ibogaine (7260) ............................. Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ...... Dimethyltryptamine (7435) ............ 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470). Dihydromorphine (9145) ............... Normorphine (9313) ...................... Amphetamine (1100) .................... Methamphetamine (1105) ............. Amobarbital (2125) ....................... Phencyclidine (7471) .................... Phenylacetone (8501) ................... Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................. VerDate Aug<31>2005 16:46 Aug 05, 2008 I I I I I I I I II II II II II II II II II II Jkt 214001 Drug Schedule Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Meperidine (9230) ......................... Metazocine (9240) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... Oxymorphone (9652) .................... Phenazocine (9715) ...................... Fentanyl (9801) ............................. II II II II II II II II II II II The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17971 Filed 8–5–08; 8:45 am] Drug Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration. Any other such applicant, and any person who is presently, registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator/Deputy Chief of Operation, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18046 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 23, 2008, Austin Pharma, LLC., 811 Paloma Drive, Suite A, Round Rock, Texas 78665– 2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Alphamethadol (9605) .................. Nabilone (7379) ............................ Methadone (9250) ........................ Methadone Intermediate (9254) ... Levo-alphacetylmethadol (9648) .. Alfentanil (9737) ........................... PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 I I I II II II II II Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 27, 2008, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ E:\FR\FM\06AUN1.SGM 06AUN1 Schedule I II II II II II II II II II II 45786 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices Drug Schedule Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ II II II II II II II II II II II II The company plans on manufacturing the listed controlled substances in bulk for sale to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than October 6, 2008. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18047 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated April 9, 2008, and published in the Federal Register on April 16, 2008, (73 FR 20718), Aldrich Chemical Company, Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342–4304, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: mstockstill on PROD1PC66 with NOTICES Drug Schedule Cathinone (1235) .......................... Methcathinone (1237) ................... N-Ethylamphetamine (1475) ......... N,N-Dimethylamphetamine (1480) Aminorex (1585) ........................... Gamma Hydroxybutyric Acid (2010). Methaqualone (2565) .................... Ibogaine (7260) ............................. VerDate Aug<31>2005 16:46 Aug 05, 2008 I I I I I I I I Jkt 214001 Drug Schedule Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ...... Mescaline (7381) .......................... 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4-Methylenedioxy-methamphetamine (7405). 4-Methoxyamphetamine (7411) .... Psilocybin (7437) .......................... Psilocyn (7438) ............................. N-Ethyl-1-phenylcyclohexylamine (7455). Dihydromorphine (9145) ............... Normorphine (9313) ...................... Acetylmethadol (9601) .................. Alphacetylmethadol except levoalphacetylmethadol (9603). Normethadone (9635) ................... Norpipanone (9636) ...................... 3-Methylfentanyl (9813) ................ Amphetamine (1100) .................... Methamphetamine (1105) ............. Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... 1-Phenylcyclohexylamine (7460) .. Phencyclidine (7471) .................... Phenylacetone (8501) ................... 1Piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................. Benzoylecgonine (9180) ............... Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Isomethadone (9226) .................... Meperidine (9230) ......................... Meperidine intermediate-A (9232) Meperidine intermediate-B (9233) Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk, (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) .................... Fentanyl (9801) ............................. I I I I I I I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Aldrich Chemical Company to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Aldrich Chemical Company to ensure that the company’s PO 00000 Frm 00094 Fmt 4703 Sfmt 4703 registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17956 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated February 12, 2008 and published in the Federal Register on February 21, 2008, (73 FR 9593), Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Lysergic acid diethylamide (7315) Tetrahydrocannabinols (THC) (7370). Alphamethadol (9605) .................. Hydromorphone (9150) ................. Benzoylecgonine (9180) ............... Methadone (9250) ........................ Morphine (9300) ........................... Schedule I I I II II II II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Roche Diagnostics Operations, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Roche Diagnostics Operations, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection E:\FR\FM\06AUN1.SGM 06AUN1

Agencies

[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Pages 45785-45786]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18047]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 27, 2008, Cody 
Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made 
application by renewal to the Drug Enforcement Administration (DEA) as 
a bulk manufacturer of the basic classes of controlled substances 
listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II

[[Page 45786]]

 
Hydromorphone (9150).......................  II
Diphenoxylate (9170).......................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans on manufacturing the listed controlled substances 
in bulk for sale to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 6, 2008.

    Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-18047 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.